Ozempic approved in Canada to slow kidney decline, prevent cardiovascular disease
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes.
Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes.
Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease.
An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection.
The patients taking the drug were also less likely to die from cardiovascular disease — another condition that affects many patients with diabetes.
The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada’s decision.
Read more: https://www.cbc.ca/news/health/ozempic-kidney-disease-diabetes-health-canada-1.7612917
Mainstream NewsBed Bug Infestation Forces Closure of Fort Simpson Schools
Two schools in Fort Simpson, N.W.T., will close starting Monday due to a bed bug infestation, with no confirmed reopening date.
Mainstream NewsThe Complex History of Bible Translations in Greenland and Labrador
Early Christian missionaries in Greenland and Labrador relied on Inuit converts to translate the Bible, revealing a complex interplay of cultural exchange and religious adaptation.
Mainstream NewsInuit-Led Pirutsiagutiit Program Replaces Child First Initiative
Federal government transfers $575M in child health and social support funding to Inuit organizations, ending uncertainty over previous program.
Mainstream NewsWhitehorse Students Engage With Canadian Astronauts Aboard the ISS
Students from Whitehorse schools connected with Canadian astronauts Jenni Gibbons and Joshua Kutryk, gaining insights into space exploration and inspiring future careers in science.